Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

May 16, 2023

Study Completion Date

August 2, 2023

Conditions
Vulvovaginal Candidiasis
Interventions
DRUG

Ibrexafungerp

Each day dosing will consist of two 150mg tablets taken BID.

Trial Locations (25)

11042

Center for Colposcopy, Lake Success

19107

Jefferson University, Philadelphia

27103

Lyndhurst Clinical Research, Winston-Salem

27607

UWCR - Raleigh, Raleigh

28303

Wake Research (Carolina Institute for Clinical Research), Fayetteville

30328

Wake (Mount Vernon Clinical Research), Atlanta

33186

New Age Medical Research, Miami

38120

Medical Research Center, Memphis

44195

Cleveland Clinic, Cleveland

48201

Wayne State University, Detroit

63131

Consultants in Women's Healthcare, St Louis

70125

Women Under Study, New Orleans

75230

Discovery Clinical Trials, Dallas

77054

TMC Life Research, Inc, Houston

78503

Discovery Clinical Trials, McAllen

83404

Clinical Research Prime, Idaho Falls

Leavitt Women's Healthcare, Idaho Falls

85032

Precision Trials, AZ, Phoenix

89123

Wake Research (CRCN), Las Vegas

92111

Women's Healthcare Research, San Diego

92120

Wake Research (MCCR), San Diego

97239

Oregon Health and Science University, Portland

98105

Seattle Clinical Research Center, Seattle

02114

Massachusetts's General, Boston

08648

Capital Health Lawrence OBGYN, Lawrenceville

All Listed Sponsors
lead

Scynexis, Inc.

INDUSTRY